Agios Pharmaceuticals

Agios Pharmaceuticals logo
🇺🇸United States
Ownership
Public
Established
2008-01-01
Employees
386
Market Cap
$2.6B
Website
http://www.agios.com
Introduction

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is...

A Study to Determine How Tebapivat is Absorbed, Broken Down, and Removed From the Body and the Extent to Which Tebapivat is Made Available in the Body in Healthy Participants

Phase 1
Not yet recruiting
Conditions
Interventions
First Posted Date
2024-12-20
Last Posted Date
2024-12-20
Lead Sponsor
Agios Pharmaceuticals, Inc.
Target Recruit Count
8
Registration Number
NCT06745271
Locations
🇺🇸

Taha El-Shahat, Madison, Wisconsin, United States

Study of How Mitapivat Affects Midazolam Blood Levels in Healthy Participants

Phase 1
Active, not recruiting
Conditions
Interventions
First Posted Date
2024-10-18
Last Posted Date
2024-11-19
Lead Sponsor
Agios Pharmaceuticals, Inc.
Target Recruit Count
20
Registration Number
NCT06648824
Locations
🇺🇸

Fortrea Clinical Research Unit Inc., Dallas, Texas, United States

A Study of Mitapivat in Participants With Sickle Cell Disease and Nephropathy

Phase 2
Not yet recruiting
Conditions
Interventions
First Posted Date
2024-02-29
Last Posted Date
2024-11-14
Lead Sponsor
Agios Pharmaceuticals, Inc.
Target Recruit Count
40
Registration Number
NCT06286046

Single and Multiple Ascending Dose Study and Food Effect Study for AG181

Phase 1
Recruiting
Conditions
Interventions
First Posted Date
2024-02-29
Last Posted Date
2024-12-20
Lead Sponsor
Agios Pharmaceuticals, Inc.
Target Recruit Count
120
Registration Number
NCT06286033
Locations
🇺🇸

ICON 1255 East 3900 South, Salt Lake City, Utah, United States

A Study to Provide Continued Access to Mitapivat for Participants Who Previously Completed an Agios-Sponsored Mitapivat Study

First Posted Date
2023-03-21
Last Posted Date
2024-11-18
Lead Sponsor
Agios Pharmaceuticals, Inc.
Target Recruit Count
6
Registration Number
NCT05777993
Locations
🇨🇦

McMaster Centre for Transfusion Medicine McMaster University, Hamilton, Ontario, Canada

🇯🇵

Toho University - Omori Medical Center, Ota-Ku, Japan

🇯🇵

Tohoku University Hospital, Sendai, Miyagi, Japan

and more 1 locations

A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function

Phase 1
Completed
Conditions
Interventions
First Posted Date
2022-11-09
Last Posted Date
2023-09-21
Lead Sponsor
Agios Pharmaceuticals, Inc.
Target Recruit Count
20
Registration Number
NCT05610657
Locations
🇺🇸

Orlando Clinical Research Center (OCRC), Orlando, Florida, United States

🇺🇸

Orange County Research Center (OCRC), Tustin, California, United States

🇺🇸

Clinical Pharmacology of Miami (CPMI), Miami, Florida, United States

A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Phase 2
Recruiting
Conditions
Interventions
First Posted Date
2022-08-05
Last Posted Date
2024-11-15
Lead Sponsor
Agios Pharmaceuticals, Inc.
Target Recruit Count
80
Registration Number
NCT05490446
Locations
🇺🇸

Innovative Clinical Research Institute Whittier, Lakewood, California, United States

🇺🇸

David Geffen School of Medicine at UCLA, Los Angeles, California, United States

🇺🇸

Emad Ibrahim, MD, Inc., Redlands, California, United States

and more 42 locations

A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period

First Posted Date
2022-01-03
Last Posted Date
2024-12-18
Lead Sponsor
Agios Pharmaceuticals, Inc.
Target Recruit Count
30
Registration Number
NCT05175105
Locations
🇺🇸

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

🇺🇸

Children's Healthcare of Atlanta - Emory, Atlanta, Georgia, United States

🇺🇸

Stanford Medicine, Palo Alto, California, United States

and more 16 locations

A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period

First Posted Date
2021-12-03
Last Posted Date
2024-12-18
Lead Sponsor
Agios Pharmaceuticals, Inc.
Target Recruit Count
49
Registration Number
NCT05144256
Locations
🇺🇸

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

🇹🇷

Ege University Faculty of Medicine, Izmir, Adana, Turkey

🇺🇸

Weill Cornell Medical College, New York, New York, United States

and more 19 locations

A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)

Phase 2
Active, not recruiting
Conditions
Interventions
First Posted Date
2021-09-02
Last Posted Date
2024-12-20
Lead Sponsor
Agios Pharmaceuticals, Inc.
Target Recruit Count
267
Registration Number
NCT05031780
Locations
🇺🇸

University of California San Diego, La Jolla, California, United States

🇺🇸

UCLA Health, Los Angeles, California, United States

🇺🇸

Children's Hospital Oakland, Oakland, California, United States

and more 97 locations
© Copyright 2024. All Rights Reserved by MedPath